Probiotic normalization of Candida albicans in schizophrenia: A randomized, placebo-controlled, longitudinal pilot study

Brain, Behavior, and Immunity

Volumn 62, Issue , 2017, Pages 41-45

  Severance, Emily G ^a   Gressitt, Kristin L ^a   Stallings, Cassie R ^b   Katsafanas, Emily ^b   Schweinfurth, Lucy A ^b   Savage, Christina L G ^b   Adamos, Maria B ^b   Sweeney, Kevin M ^b   Origoni, Andrea E ^b   Khushalani, Sunil ^b   Dickerson, Faith B ^b   Yolken, Robert H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHEPPARD PRATT HEALTH SYSTEM   (United States)

Author keywords

Autism; Fungus; Gastroenterology; Infection; Mental health; Sex differences

Indexed keywords

FUNGUS ANTIBODY; PROBIOTIC AGENT; BACTERIUM ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PILOT STUDY; SACCHAROMYCES CEREVISIAE; SCHIZOPHRENIA; SERODIAGNOSIS; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; TREND STUDY; ADOLESCENT; AGED; DRUG EFFECT; GASTROINTESTINAL TRACT; IMMUNOLOGY; INTESTINE FLORA; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BACTERIAL; CANDIDA ALBICANS; FEMALE; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PILOT PROJECTS; PROBIOTICS; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85007502866     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2016.11.019     Document Type: Article

References (21)

1. APA, Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. fourth ed., 2000, American Psychiatric Association, Washington, DC.
2. Castro-Nallar, E., Bendall, M.L., Perez-Losada, M., Sabuncyan, S., Severance, E.G., Dickerson, F.B., Schroeder, J.R., Yolken, R.H., Crandall, K.A., Composition, taxonomy and functional diversity of the oropharynx microbiome in individuals with schizophrenia and controls. PeerJ, 3, 2015, e1140.
3. Cryan, J.F., Dinan, T.G., Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci. 13 (2012), 701–712.
4. Davar, R., Nokhostin, F., Eftekhar, M., Sekhavat, L., Bashiri Zadeh, M., Shamsi, F., Comparing the recurrence of vulvovaginal candidiasis in patients undergoing prophylactic treatment with probiotic and placebo during the 6 months. Probiotics Antimicrob. Proteins 8 (2016), 130–133.
5. Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Khushalani, S., Yang, S., Yolken, R., C-reactive protein is elevated in schizophrenia. Schizophr. Res. 143 (2013), 198–202.
6. Dickerson, F.B., Stallings, C., Origoni, A., Katsafanas, E., Savage, C.L., Schweinfurth, L.A., Goga, J., Khushalani, S., Yolken, R.H., Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial. Prim. Care Companion CNS Disord, 16, 2014.
7. Dickerson, F., Stallings, C., Origoni, A., Katsafanas, E., Schweinfurth, L.A., Savage, C.L., Khushalani, S., Yolken, R., Pentraxin 3 is reduced in bipolar disorder. Bipolar Disord. 17 (2015), 409–414.
8. Fond, G., Boukouaci, W., Chevalier, G., Regnault, A., Eberl, G., Hamdani, N., Dickerson, F., Macgregor, A., Boyer, L., Dargel, A., et al. The “psychomicrobiotic”: targeting microbiota in major psychiatric disorders: a systematic review. Pathol. Biol. (Paris) 63 (2015), 35–42.
9. Ghannoum, M.A., Jurevic, R.J., Mukherjee, P.K., Cui, F., Sikaroodi, M., Naqvi, A., Gillevet, P.M., Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PLoS Pathog., 6, 2010, e1000713.
10. Kay, S.R., Fiszbein, A., Opler, L.A., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987), 261–276.
11. Kim, J., Sudbery, P., Candida albicans, a major human fungal pathogen. J Microbiol. 49 (2011), 171–177.
12. Mailander-Sanchez, D., Wagener, J., Schaller, M., Potential role of probiotic bacteria in the treatment and prevention of localised candidosis. Mycoses 55 (2012), 17–26.
13. Matsubara, V.H., Wang, Y., Bandara, H.M., Mayer, M.P., Samaranayake, L.P., Probiotic lactobacilli inhibit early stages of Candida albicans biofilm development by reducing their growth, cell adhesion, and filamentation. Appl. Microbiol. Biotechnol. 100 (2016), 6415–6426.
14. McKenzie, H., Main, J., Pennington, C.R., Parratt, D., Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut 31 (1990), 536–538.
15. Severance, E.G., Alaedini, A., Yang, S., Halling, M., Gressitt, K.L., Stallings, C.R., Origoni, A.E., Vaughan, C., Khushalani, S., Leweke, F.M., et al. Gastrointestinal inflammation and associated immune activation in schizophrenia. Schizophr. Res. 138 (2012), 48–53.
16. Severance, E.G., Gressitt, K.L., Stallings, C.R., Origoni, A.E., Khushalani, S., Leweke, F.M., Dickerson, F.B., Yolken, R.H., Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr. Res. 148 (2013), 130–137.
17. Severance, E.G., Gressitt, K.L., Stallings, C.R., Katsafanas, E., Schweinfurth, L.A., Savage, C.L., Adamos, M.B., Sweeney, K.M., Origoni, A.E., Khushalani, S., et al. Candida albicans exposures, sex specificity and cognitive deficits in schizophrenia and bipolar disorder. NPJ Schizophr., 2, 2016, 16018.
18. Suhr, M.J., Hallen-Adams, H.E., The human gut mycobiome: pitfalls and potentials-a mycologist's perspective. Mycologia 107 (2015), 1057–1073.
19. Tomasik, J., Yolken, R.H., Bahn, S., Dickerson, F.B., Immunomodulatory effects of probiotic supplementation in schizophrenia patients: a randomized placebo-controlled trial. Biomark Insights 10 (2015), 47–54.
20. Yarandi, S.S., Peterson, D.A., Treisman, G.J., Moran, T.H., Pasricha, P.J., Modulatory effects of gut microbiota on the central nervous system: how gut could play a role in neuropsychiatric health and diseases. J. Neurogastroenterol. Motil. 22 (2016), 201–212.
21. Yolken, R.H., Severance, E.G., Sabunciyan, S., Gressitt, K.L., Chen, O., Stallings, C., Origoni, A., Katsafanas, E., Schweinfurth, L.A.B., Savage, C.L.G., et al. Metagenomic sequencing indicates that the oropharyngeal phageome of individuals with schizophrenia differs from that of controls. Schizophr. Bull. 41 (2015), 1153–1161.